CL2020001852A1 - Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066) - Google Patents

Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066)

Info

Publication number
CL2020001852A1
CL2020001852A1 CL2020001852A CL2020001852A CL2020001852A1 CL 2020001852 A1 CL2020001852 A1 CL 2020001852A1 CL 2020001852 A CL2020001852 A CL 2020001852A CL 2020001852 A CL2020001852 A CL 2020001852A CL 2020001852 A1 CL2020001852 A1 CL 2020001852A1
Authority
CL
Chile
Prior art keywords
ketamine
processes
preparation
products derived
hydrochloride
Prior art date
Application number
CL2020001852A
Other languages
English (en)
Inventor
Cheng Yi Chen
Oliver Floegel
Michael Justus
Adrian Maurer
Karl Reuter
Tobias Wedel
Tobias Strittmatter
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56068863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020001852(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2020001852A1 publication Critical patent/CL2020001852A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/23—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procesos de preparación de S-ketamina o clorhidrato de S-ketamina o productos derivados de éste.
CL2020001852A 2015-05-13 2020-07-13 Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066) CL2020001852A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562160659P 2015-05-13 2015-05-13

Publications (1)

Publication Number Publication Date
CL2020001852A1 true CL2020001852A1 (es) 2020-10-23

Family

ID=56068863

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2017002854A CL2017002854A1 (es) 2015-05-13 2017-11-10 Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamin
CL2019001066A CL2019001066A1 (es) 2015-05-13 2019-04-18 Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
CL2020001852A CL2020001852A1 (es) 2015-05-13 2020-07-13 Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2017002854A CL2017002854A1 (es) 2015-05-13 2017-11-10 Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamin
CL2019001066A CL2019001066A1 (es) 2015-05-13 2019-04-18 Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)

Country Status (24)

Country Link
US (3) US20160332962A1 (es)
EP (1) EP3294704B1 (es)
JP (1) JP6882990B2 (es)
KR (1) KR102610047B1 (es)
CN (1) CN107750245B (es)
AU (1) AU2016260911B2 (es)
BR (1) BR112017024243B1 (es)
CA (1) CA2985696A1 (es)
CL (3) CL2017002854A1 (es)
CO (1) CO2017011553A2 (es)
CR (1) CR20170517A (es)
EA (1) EA201792503A1 (es)
EC (1) ECSP17075386A (es)
ES (1) ES2767708T3 (es)
GT (1) GT201700245A (es)
IL (1) IL255433B2 (es)
MX (1) MX377053B (es)
MY (1) MY181938A (es)
PE (1) PE20180527A1 (es)
PH (2) PH12017502024B1 (es)
SA (1) SA517390322B1 (es)
UA (1) UA121049C2 (es)
WO (1) WO2016180984A1 (es)
ZA (1) ZA201708417B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
EP3193853A1 (en) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
DK3505157T3 (da) * 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN110218157B (zh) * 2018-03-01 2022-08-23 江苏恒瑞医药股份有限公司 一种r-氯胺酮及其可药用盐的制备方法
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
CN108659004B (zh) * 2018-07-12 2020-11-10 福安药业集团重庆博圣制药有限公司 奥拉西坦异构体的制备方法
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
EP3934632A4 (en) 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
EP3956300A1 (en) * 2019-04-16 2022-02-23 Janssen Pharmaceutica NV Synthetic methods of preparing esketamine
CN112375005A (zh) * 2019-08-16 2021-02-19 国药集团工业有限公司 一种氯胺酮、其衍生物或其盐的消旋化方法
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
WO2022208144A1 (en) * 2021-03-31 2022-10-06 Supriya Lifescience Ltd A crystalline form of 2-(2-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride and method thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) * 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS5857420B2 (ja) * 1975-02-12 1983-12-20 ワコウジユンヤクコウギヨウ カブシキガイシヤ Ｄｌ− フエニルグリシンノ コウガクブンカツホウホウ
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
JPS6314771A (ja) * 1986-07-08 1988-01-21 Sankyo Co Ltd 光学活性イミダゾ−ル誘導体およびその製法
JPS63192753A (ja) * 1987-02-05 1988-08-10 Otsuka Pharmaceut Co Ltd テトラヒドロキノリン誘導体の光学分割法
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
CA2202911A1 (en) 1994-10-17 1996-04-25 Cor Peter Mathilde Gerard A'campo Process for separating enantiomers from a racemic mixture
PE8798A1 (es) 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
DE19619665C2 (de) * 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
TW430660B (en) * 1996-05-30 2001-04-21 Mochida Pharm Co Ltd Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
CA2338457C (en) 1998-07-24 2009-11-17 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
BRPI0002693B8 (pt) * 2000-06-19 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
PT2010544E (pt) * 2006-04-21 2009-11-03 Zach System Spa Processo de preparação de dorzolamida
EP2029136A4 (en) 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc TREATMENT FOR DEPRESSION DISEASES
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
WO2009131794A1 (en) * 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
AU2011267474B2 (en) 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US9012486B2 (en) * 2011-11-14 2015-04-21 Alex Chervinsky Topical composition for pain relief
CN104053785A (zh) 2011-11-14 2014-09-17 综合医院公司 为患有抑郁症的受试者选择治疗方案的测定法和方法
WO2013138322A1 (en) 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX2015002378A (es) 2012-08-23 2015-09-25 Stuart L Weg Composicion ansiolitica, formulacion y metodo de uso.
AU2013328280B2 (en) * 2012-10-08 2017-12-21 Auckland Uniservices Limited Ketamine derivatives
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
PH12021552333A1 (en) 2013-03-15 2022-08-01 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrocholoride
KR20220044380A (ko) 2013-04-12 2022-04-07 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
DK3043785T3 (da) * 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression

Also Published As

Publication number Publication date
EP3294704A1 (en) 2018-03-21
MX377053B (es) 2025-03-07
PH12021552213A1 (en) 2022-07-18
AU2016260911B2 (en) 2020-02-27
CL2019001066A1 (es) 2019-06-21
US20160332962A1 (en) 2016-11-17
US20180282266A1 (en) 2018-10-04
CR20170517A (es) 2017-12-05
GT201700245A (es) 2019-08-07
PH12017502024B1 (en) 2023-04-05
US10815196B2 (en) 2020-10-27
HK1251546A1 (zh) 2019-02-01
CL2017002854A1 (es) 2018-04-20
CN107750245B (zh) 2021-06-22
IL255433A (en) 2018-02-28
ZA201708417B (en) 2018-11-28
SA517390322B1 (ar) 2023-07-16
MY181938A (en) 2021-01-14
MX2017014473A (es) 2018-03-21
PH12017502024A1 (en) 2018-04-02
WO2016180984A1 (en) 2016-11-17
JP2018516891A (ja) 2018-06-28
KR20180008568A (ko) 2018-01-24
ES2767708T3 (es) 2020-06-18
JP6882990B2 (ja) 2021-06-02
CO2017011553A2 (es) 2018-04-19
UA121049C2 (uk) 2020-03-25
CN107750245A (zh) 2018-03-02
AU2016260911A1 (en) 2017-11-16
PE20180527A1 (es) 2018-03-19
BR112017024243B1 (pt) 2021-12-07
EA201792503A1 (ru) 2018-02-28
ECSP17075386A (es) 2018-02-28
US20210024461A1 (en) 2021-01-28
CA2985696A1 (en) 2016-11-17
EP3294704B1 (en) 2019-10-30
BR112017024243A2 (pt) 2018-07-17
IL255433B1 (en) 2023-03-01
KR102610047B1 (ko) 2023-12-05
IL255433B2 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
EP3459925A4 (en) METHOD FOR PRODUCING 2-HYDROXYL-4- (2,3-DISUBSTITUTED BENZYLOXY) -5-SUBSTITUTED BENZALDEHYDE DERIVATIVE
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA45155A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
EP3706725A4 (en) METHOD OF MANUFACTURING TAPINAROF
IL260730B (en) Process for preparing terpinene-4-ol
MA45183A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA49775A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
HUE052833T2 (hu) Eljárás 2,5-furándikarbonsav (FDCA) elõállítására
IL282114A (en) Processes for preparing functionalized cyclooctenes
CL2019000050A1 (es) Procesos para la preparacion de oxipicolinamidas 4 - alkoxi - (acil o aquil).
IT201600105178A1 (it) Procedimento per la produzione di dieni
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
EP3511313A4 (en) METHOD FOR PRODUCING 1,3-CYCLOHEXANDIMETHANOL
MA45362A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
EP3390368A4 (en) PROCESS FOR PREPARING SUBSTITUTED 5,6-DIHYDRO-6-PHENYL BENZO [F] ISOCHINOLINE-2-AMINE
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
EP3505525A4 (en) METHOD FOR PRODUCING RUBUSOSIDE
HUE055374T2 (hu) Eljárás Lenvatinib elõállítására
EP3666756A4 (en) METHOD FOR PRODUCING LEVETIRACETAM
EP3395786A4 (en) PROCESS FOR PREPARING BUTADIENE
EP3533856A4 (en) METHOD FOR PRODUCING HEXADECAHYDROPYRENE
IL258663B (en) Industrial process for the preparation of (5s,10s)-10-benzyl-16-methyl-11,14,18-trioxo-15,17,19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium (e)-3-carboxyacrylate salt
IL271388B (en) Improved process for preparing imetelstat
FR3049599B1 (fr) Procede de preparation de l'hexafluorobutadiene.
WO2016125185A3 (en) Process for the preparation of 4-substituted-1-(trifluoromethoxy)benzene compounds